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Several point mutations in the mouse pro-
foundly affect the metabolic characteristics
of the animal. As examples may be cited the
"muscular dystrophy" mutation (dy), the
"obese" and "diabetes" mutations (ob,db),
the "yellow" mutations (AY,AVy,etc.) at the
agouti locus, the two "pituitary dwarf" mut-
ations (dw,df), and several mutations affec-
ting body size, e.g., "pygmy" (pg) (1). In
none of these cases has the polypeptide dir-
ectly altered by the mutation yet been iden-
tified. In the case of the obese obob mutant
the primary lesion remains unknown in spite
of more than 20 years of effort by numerous
investigators.
Most "visible" mutations, such as those
affecting coat color, eye color, and other
morphological and neurological characteris-
tics, also fall into this category of mutations
in which the primary polypeptide lesion is
unknown. The affected characteristics, in
general, result from the interactions of many
developmental processes and metabolic path-
ways. The mutations presumably alter poly-
peptides which are involved at branchpoints
or critical rate-limiting steps in one or more
of the interacting metabolic pathways. Thus
the influence of these mutations is exerted
at some point prior to the final definition of
the particular characteristic by which each
mutant is recognized. These considerations
suggest that the majority of these muta-
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tions also induce alterations in metabolic
and physiologic parameters other than those
involved in the development of the most ob-
vious phenotypic effect.
An example of an indirect ("pleiotropic")
effect of a mutation on the catalytic cap-
acity of a particular enzyme is the hepatic
malic enzyme level in yellow (Ay/-,Av/y-)
mice. Under various physiological conditions
and on different genomic backgrounds, hep-
atic malic enzyme activity was always higher
in the yellow mice than in their black sibs
(2,3). Since these yellow and black sibs dif-
fer by only a single mutant gene at the
agouti locus, the most obvious conclusion
might be that the agouti locus is the struc-
tural locus for the cytoplasmic malic enzyme
of the liver. This is, however, not the case.
The structural locus for the enzyme (Mod-i)
is located on chromosome 9, whereas the
agouti locus is located on chromosome 2.
Consequently, this characteristic of yellow
mice appears to be a pleiotropic effect of the
Ay and AVY mutations.
Differences between yellow and nonyel-
low sibling mice with respect to other hepa-
tic enzyme capacities have also been ob-
served. These appeared to result from inter-
action of the metabolic effect of the "yellow"
mutations with the metabolic characteristics
induced by the background strain genome (3)
and therefore could also be considered to be
pleiotropic effects of the mutations.
Numerous mutations in the mouse have
been detected through their alteration of
December 1973 211specific enzyme proteins as determined by
electrophoretic techniques. Here, the pri-
mary lesion provides the basis for identifi-
cation and localization of the mutation.
However, in most cases the effects of the al-
tered enzyme protein on the metabolic econ-
omy of the animal are unknown.
Methodology for detecting electrophoreti-
cally altered enzyme proteins and identifi-
cation of the responsible mutations is at an
advanced stage. However, no information
regarding the metabolic importance of the
detected variants can be obtained by sole
reliance on these techniques.
At present, methodology for detecting
mutations in which the phenotypes are ex-
pressed pleiotropically is limited to the spe-
cific locus test. This test is an easy, reliable,
and accurate method for detecting muta-
tions which have been induced at specifi-
cally identified loci. Its major limitation is
the relatively small number of loci, at which
"visible" mutations occur, which can be car-
ried as recessive homozygotes in one or a
few tester stocks because of deleterious ef-
fects on viability and fertility. Because dif-
ferent loci have varying degrees of sensitiv-
ity to different mutagens, this limitation is
a serious one, especially from the point of
view of assessing the relative mutagenicity
of different substances and of different for-
mulations of the same substance. In order
to obtain valid data in this area, it is neces-
sary to assay as large a proportion of the
total genome as possible. This requirement
is especially important if only one or, at
best, a few assay systems are to be used for
assessing the relative mutagenicity of large
numbers of unrelated compounds.
Little, if anything, is known about the
particular types of mutagenic changes rep-
resented by "pleiotropic" mutations. It is
not known, for example, whether such mu-
tations are induced generally by different
classes of mutagens than mutations charac-
terized solely by electrophoretic alterations.
If the latter type of mutation has no ap-
parent metabolic effects on the individual
in its present environment, it may represent
a mechanism of "preadaptation" for sur-
vival in an altered environment. Such mu-
tations appear to be widespread in wild
mouse populations and may represent me-
tabolically and selectively "neutral" muta-
tions.
Since mutations which alter only the
electrophoretic properties of enzymes may
differ from those which induce numerous
pleiotropic effects in the relative threats
they pose to the individual and to the popu-
lation, it seems important to determine
whether they, indeed, are induced by dif-
ferent classes of mutagens. In order to an-
swer this question it is necessary first to de-
velop assays to detect chemically induced
pleiotropic mutations at a much larger num-
ber of loci than is possible with the present
specific locus test.
From the viewpoint of a regulatory
agency the information of particular inter-
est is whether a substance is mutagenic and,
if it is, its degree of mutagenicity in rela-
tion to other substances. To determine
whether a substance is mutagenic, it is not
necessary to identify the loci at which it has
induced mutations. From a scientific view-
point, however, the identification and lo-
calization of the individual chemically-
induced mutations is of great importance.
This is especially true of those mutations
which may have potential utility in other
areas of bio-medical research and also in
those cases where it may be necessary to
quantify risk.
On the basis of the foregoing rationale,
Mammalian Genetics Branch, Division of
Mutagenic Research, plans to develop meth-
ods to detect chemically induced pleiotropic
mutations in genetically identified and con-
trolled mice. The plans include use of assays
of a series of enzyme activities to detect
heritable alterations in certain characteris-
tics of enzyme behavior such as thermolabil-
ity, inducibility, degradation, allosteric regu-
lation, and kinetic response to changes in
the hormonal balance. In general, these en-
zymatic parameters are governed by condi-
tions in the intracellular environment.
Therefore, much of the data obtained in
these studies will relate to mutations which,
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lar environment, either in specific tissues
or in the animal as a whole. Breeding tests
will be used to ascertain whether specific
alterations are heritable or largely environ-
mental in origin. It is anticipated that po-
tentially useful mutations may be identi-
fied and preserved as a result of these tests.
Assays for detecting those mutations
which appear to alter only the electrophore-
tic properties of specific enzyme proteins
will also be employed in conjunction with
the same experimental systems. Therefore,
it should be possible to explore in some de-
tail whether these supposedly "neutral"
heritable changes actually do exert more or
less subtle influences on the metabolic equi-
librium or are truly without effect.
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